Top of this page
Skip navigation, go straight to the content
Scroll down to discover UCB
bimekizumab - UCB4940
| Disease area studied |
Abbreviated title | Phase | Study ID | Registry database | Study results | Lay summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Ankylosing Spondylitis | A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
AS0008 Completed |
NCT02963506 2016-001102-42 |
|
van der Heijde D., Arthritis Rheumatol 2019; 71(Suppl 10), abs 0937 | ||
| Ankylosing Spondylitis | A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis |
AS0009 Ongoing |
|||||
| Nonradiographic Axial Spondyloarthritis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis |
AS0010 Ongoing |
|
||||
| Ankylosing Spondylitis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
AS0011 Ongoing |
|||||
| Ankylosing Spondylitis | Study to evaluate the efficacy and safety of Bimekizumab compared to Certolizumab Pegol in the treatment of subjects with active ankylosing spondylitis (AS) |
AS0013 Ongoing |
NCT03215277 | ||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) |
DV0002 Ongoing |
|
||||
| Psoriatic Arthritis | The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI). |
DV0004 Ongoing |
NCT04109976 | ||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) |
DV0006 Ongoing |
|
||||
| Hidradenitis Suppurativa | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. |
HS0001 Completed |
NCT03248531 | ||||
| Psoriatic Arthritis | A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis |
PA0008 Completed |
NCT02969525 2016-001103-23 |
Ritchlin C.T. et al. The Lancet 2020; 395(10222):427–40 |
|||
| Psoriatic Arthritis | A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis |
PA0009 Ongoing |
|||||
Psoriatic Arthritis |
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
PA0010 Ongoing |
|||||
| Psoriatic Arthritis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
PA0011 Ongoing |
|||||
| Psoriatic Arthritis |
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
PA0012 Ongoing |
|
||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0008 Ongoing |
NCT03412747 |
||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0009 Completed |
|||||
| Chronic Plaque Psoriasis | Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients with Chronic Plaque Psoriasis |
PS0010 Completed |
NCT02905006 |
|
Papp K.A., et al. J Am Acad Dermatol 2018; 79(2):277–286 | ||
| Chronic Plaque Psoriasis | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis |
PS0011 Completed |
NCT03010527 |
Blauvelt, A. et al. Ann Rheum Dis 2019; 78 (Suppl. 2), s. 1834 |
|||
| Chronic Plaque Psoriasis | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0013 Ongoing |
NCT03410992 | ||||
Chronic Plaque Psoriasis |
A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0014 Ongoing |
|||||
| Chronic Plaque Psoriasis | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0015 Ongoing |
|||||
| Chronic Plaque Psoriasis | A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
PS0016 Completed |
|||||
| Chronic Plaque Psoriasis | A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. |
PS0018 Completed |
|||||
| Rheumatoid arthritis | Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis |
RA0123 Completed |
NCT02430909 2014-003307-30 |
|
Glatt et al. Annals of the rheumatic diseases 2019 [ePub] | ||
| Ulcerative Colitis | A study to test the effectiveness of bimekizumab as a treatment for ulcerative colitis to look for unwanted side effects and to measure how the drug is distributed, modified and cleared from the body. |
UC0011 Terminated |
2016-000420-26 |
|